Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Uppsala – page 25

335 clinical trials in Uppsala, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Uppsala at a glance
335
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

335 trials in Uppsala

Open in trial search

Adenocarcinoma of colon

Not recruiting

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Rituximab and Drug Combination for Treating Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Abiraterone Acetate
  • Sponsor:Universitaetsklinikum Muenster AöR

Breast cancer stage III+3

Not recruiting

Study on Preoperative Treatment for HER2 Positive Breast Cancer Using Docetaxel, Pertuzumab, and Trastuzumab in Patients with Primary Breast Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Karolinska University Hospital

Complications of transplanted kidney+1

Not recruiting

Study on ARGX-117 for Improving Kidney Function in Patients with Delayed Graft Function After Deceased Donor Transplant

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Small cell lung cancer extensive stage

Not recruiting

Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Colorectal cancer metastatic

Not recruiting

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Study on the Safety and Effectiveness of Epcoritamab with a Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Safety and Effects of AZD4831 for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) with Fibrosis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD4831
  • Sponsor:AstraZeneca AB

Hodgkin's disease

Not recruiting

Study Comparing Pembrolizumab and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Uppsala

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic breast cancer and prostate cancer treatments, including targeted therapies and novel drug combinations.

  • Advanced breast cancer treatments
  • Prostate cancer therapies
  • Colorectal cancer studies

Particular emphasis on HER2-positive breast cancer imaging and treatment optimization.

02 Metabolic Disorders

Research initiatives targeting obesity management and metabolic health, with studies evaluating new therapeutic approaches for weight management in both adults and adolescents.

  • Weight management treatments
  • Adolescent obesity studies
  • Metabolic health interventions

Focus on innovative drug combinations and long-term effectiveness studies.

03 Cardiovascular and Renal Studies

Comprehensive research on heart failure prevention and chronic kidney disease management, investigating new therapeutic combinations.

  • Heart failure prevention
  • Kidney disease treatments
  • Hypertension management

Emphasis on combination therapies and preventive approaches.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.